66th ASH Annual Meeting: 602. Myeloid Oncogenesis: Basic: Cellular Mechanisms and Therapeutic Strategies

Symposia: Myeloid Oncogenesis: Basic Oral and Poster Abstracts
Oral

Research, Fundamental Science, Acute Myeloid Malignancies, AML, MDS, Apoptosis, Translational Research, MPN, CHIP, CML, Genomics, Bioinformatics, Chronic Myeloid Malignancies, Hematopoiesis, Diseases, Metabolism, Myeloid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Pathogenesis, Omics technologies

Room 6A (San Diego Convention Center)

Moderators:

Elvin Wagenblast, PhD, Icahn School of Medicine and Diu T.T. Nguyen, PhD, Barts Cancer Institute, Queen Mary University of London

Disclosures:

No relevant conflicts of interest to declare.

9:30 AM

4097

Deciphering EZH2 Non-Canonical Activities in AML Resistance

Lia N'guyen¹^*, Emeline Boet, PhD²^*, Camille Montersino¹^*, Claire Burny¹^*, Stéphane Audebert, PhD¹^*, Luc Camoin, PhD¹^*, Rémy Castellano, PhD¹^*, Sylvain Garciaz, MD, PhD¹^*, Atsushi Iwama, MD, PhD^3,4, Jean-Emmanuel Sarry, PhD²^*, Estelle Duprez, PhD¹^* and Mathilde Poplineau¹^*

¹Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, INSERM UMR1068, CNRS UMR7258, Aix Marseille Université U105, Marseille, France
²Centre de Recherche en Cancérologie de Toulouse, INSERM, Toulouse, France
³Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
⁴University of Tokyo, Tokyo, TKY, Japan

9:45 AM

The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia

Jie Sun¹^*, Shaoqi Zhang, PhD²^*, Ran Du³^*, Yue Zang³^*, Yongjin Liu⁴^*, Zhihui Li⁵^*, Diange Jin²^*, Rong Fan³^*, Lina Liu, MS⁶^*, Jun Liu⁷^*, Yue Liang, MS³^*, Shang Lou³^*, Xiaoqing Zou⁸^*, Bian Wei³^*, Yin Zhao, MS³^*, Rong Wang²^*, Yanan Wang³^*, Tong Wu, MD⁵, Jinyan Huang⁴^*, Hongshan Guo^2,3^* and Shanshan Pei, PhD^9,10^*

¹Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
²Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
³Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
⁴Biomedical big data center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁵Department of Bone Marrow Transplantation, Beijing GoBroad Boren Hospital, Beijing, China
⁶Bone Marrow Transplantation Center of The First Affiliated Hospital, Zhejiang University School of Medicine, HAMILTON, ON, Canada
⁷Liangzhu Laboratory, Zhejiang University, Hangzhou, China
⁸Liangzhu Laboratory, Zhejiang University School of Medicine, hangzhou, China
⁹Liangzhu Laboratory, Zhejiang University, Hangzhou, Zhejiang, China
¹⁰Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, hangzhou, China

10:00 AM

MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2

Mark J Althoff, PhD¹, Mohd Minhajuddin, PhD¹^*, Brett M Stevens, PhD, BS¹^*, Austin E Gillen, PhD¹^*, Regan Miller, MS¹^*, Ana Vujovic, PhD¹^*, Sweta B Patel, PhD¹^*, William Showers, MS¹^*, Stephanie Gipson, MS¹^*, Monika Dzieciatkowska, Ph.D¹^*, Jana M Ellegast, MD^2,3,4, Tristen Wright, PhD^5,6^*, Kimberly Stegmaier, MD^2,3,7, Joseph T Opferman, PhD^5,6^* and Craig T Jordan, PhD¹

¹Division of Hematology, University of Colorado Anschutz Medical Campus, Aurora, CO
²Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
³Broad Institute of MIT and Harvard, Cambridge, MA
⁴Department of Medical Oncology, University Hospital of Zurich, Zurich, Switzerland
⁵Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN
⁶Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN
⁷Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA

10:15 AM

TET2 Regulates Stability of Mismatch Repair Protein MSH6 and Helps Maintain Genomic Stability Independent of Its Dioxygenase Function

Dongxu Jiang, PhD^1,2, Yahan Zhang, MS^1,2, Xiaorong Gu, PhD²^*, Daniel J Vail¹^*, Jill Durkin¹^*, Simon Schlanger, MS¹^*, J. Joseph Melenhorst, PhD³, Jaroslaw Maciejewski⁴ and Babal K. Jha, PhD^1,2

¹Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
³Center for Immunotherapy and Precision Immuno-Oncology, Cell Therapy & Immuno-Engineering Program, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
⁴Taussig Cancer Center, Cleveland, OH

10:30 AM

The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53-Mutant Clonal Hematopoiesis

Jonas Fullin, MSc¹^*, Ebru Topçu, MSc¹^*, Roman R. Schimmer, MD²^*, Nancy Klemm, MSc¹^*, Karolina Zielinska, PhD¹^*, Christian Koch, MD¹^*, Francisco Caiado, PhD²^*, Cyril Doerdelmann, PhD³^*, Melissa Lock, MSc²^*, Joelle Tchinda, PhD⁴, Markus G. Manz, MD¹, Massimo Lopes, PhD³^* and Steffen Boettcher, MD¹^*

¹Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
²Department for Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
³Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland
⁴Laboratory for Oncology, Children's Hospital Zurich, Zurich, Switzerland

10:45 AM

Recurrent ASXL1 Mutations Promote Myeloid Malignancies through Unleashed Condensation

Maria Latacz^1,2^*, Yansu Song, PhD¹^*, Yi Hao, PhD¹^*, Marta Cykowiak, PhD¹^*, Julia Kirylczuk, MS¹^*, Jing Hu, PhD¹^*, Bi Shi, PhD¹^* and Hao Jiang, PhD^1,3

¹Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA
²Faculty of Medicine, Collegium Medicum, Univeristy of Warmia and Mazury, Olsztyn, Poland
³UVA Comprehensive Cancer Center, University of Virginia School of Medicine, Charlottesville, VA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

602A.O2.6 602. Myeloid Oncogenesis: Basic: Cellular Mechanisms and Therapeutic Strategies